^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
09/20/2023
Excerpt:
Endometrial Carcinoma: SYSTEMIC THERAPY FOR ENDOMETRIAL CARCINOMA…Useful in Certain Circumstances…ER-positive tumors...Letrozole/abemaciclib…
Secondary therapy:
letrozole
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Abemaciclib + Letrozole +/- Metformin in Recurrent or Persistent Endometrial Cancer

Excerpt:
...- Participants must have ER-positive disease, defined as ≥ 1 percent of tumor cell nuclei being immunoreactive by immunohistochemistry (IHC)....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 4851: Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models

Published date:
05/15/2020
Excerpt:
Combination treatment with letrozole and abemaciclib was significantly more efficacious when compared with either drug alone, in both SKOV3 and Ishikawa. The CI values (0.5 and 0.7, respectively) demonstrated potent synergism in these ER+…
Secondary therapy:
letrozole
DOI:
10.1158/1538-7445.AM2020-4851